Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS
Study sponsor: MediciNova
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-06-30Actual
Enrollment · participants34Actual
Source updated2024-10-30Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.